Trial Profile

Histamine dihydrochloride and interleukin-2 in patients with acute myeloid leukaemia in first complete remission.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 28 May 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Histamine dihydrochloride (Primary) ; Interleukin-2
Indications Acute myeloid leukaemia
Focus Registrational; Therapeutic Use

Most Recent Events

30 Mar 2012 Status changed from planning to discontinued, according to EpiCept's 2011 Form 10-K
27 Jun 2011 FDA advises that the protocol be amended to include an Interleukin-2 monotherapy arm (decision pending).
10 May 2011 EpiCept files protocol with the FDA, according to a company media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com